Market Research Logo

Global Liver Cirrhosis Market 2016-2020

About Cirrhosis of the Liver

Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

Technavio’s analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck
Other prominent vendors
  • Bristol-Myers Squibb
  • Conatus Pharmaceuticals
  • Gwo Xi Stem Cell Applied Technology
  • Instituto Grifols
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine
  • Pharmicell
  • Salix Pharmaceuticals
  • Stempeutics Research
Market driver
  • High prevalence of liver cirrhosis
  • For a full, detailed list, view our report
Market challenge
  • Adverse effects of drugs
  • For a full, detailed list, view our report
Market trend
  • Use of off-label drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Liver Cirrhosis Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global liver cirrhosis therapeutics market: F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, and Merck.

Other Prominent Vendors in the market are: Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, and Stempeutics Research.

Commenting on the report, an analyst from Technavio’s team said: “A noticeable trend in the market is the use of off-label drugs. Off-label drugs are unapproved medications that are used in the treatment of diseases. For instance, apart from multivitamins and mineral supplements, disulfiram, naltrexone, acamprosate, ciprofloxacin, norfloxacin, ceftriaxone, ofloxacin, amoxicillin-clavulanate, and phytonadione are among the off-label drugs available for the treatment of liver cirrhosis.”

According to the report, a growth driver of this market is the high prevalence of liver cirrhosis. Alcohol has been identified as the strongest risk factor for liver cirrhosis, other than diabetes and hepatitis C, which together constitutes for over 50% of all cirrhosis cases. Relevant health efforts are required to reduce this disease burden, specifically among ethnic minorities and individuals living below the poverty level. As per a studies published, liver cirrhosis affects over 633,000 people every year. It also stated that more than 68% of these individuals may not know that they have the disease, raising the possibility of a large number of undiagnosed cases of liver cirrhosis.

Further, the report states that a challenge that could impact market growth is the adverse effects of drugs used to treat this medical issue.

Companies Mentioned

F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, Stempeutics Research.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
      • Table Stages of liver diseases
    • Etiology
      • Table Causes of liver cirrhosis
    • Symptoms
    • Pathophysiology
    • Diagnosis
      • Table Diagnosis of liver cirrhosis
    • Epidemiology
    • Prevention
    • Treatment
    • Impact of alcohol consumption on liver cirrhosis
      • Table Effect of alcohol consumption on liver cirrhosis
  • Pipeline portfolio
    • Table Pipeline molecules for liver cirrhosis
    • Information on pipeline candidates
    • Clinical trials for liver cirrhosis
      • Table Clinical trials by development phase
      • Table Clinical trials by trial status
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global liver cirrhosis therapeutics market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of molecule
    • Biologics
    • Small molecules
  • Market segmentation by types of liver cirrhosis
    • Table Four main types of liver cirrhosis
    • Table Market share by types of liver cirrhosis
  • Market segmentation by types of liver cirrhosis treatment
    • Table Types of treatment for liver cirrhosis
    • Therapeutics to treat causes of liver cirrhosis
    • Therapies to treat complications of liver cirrhosis
  • Geographical segmentation
    • Table Global liver cirrhosis Therapeutics market segment by geography 2015
    • Table Global liver cirrhosis Therapeutics market segment by geography 2015-2020 ($millions)
    • Liver cirrhosis therapeutics market in Americas
      • Market overview
    • Market size and forecast
      • Table Liver cirrhosis therapeutics market in Americas ($ millions)
    • Liver cirrhosis therapeutics market in EMEA
      • Market overview
    • Market size and forecast
      • Table Liver cirrhosis therapeutics market in EMEA ($ millions)
    • Liver cirrhosis therapeutics market in APAC
      • Market overview
    • Market size and forecast
      • Table Liver cirrhosis therapeutics market in APAC ($ billions)
  • Market drivers
    • High prevalence of liver cirrhosis
    • Advances in technology
    • High unmet medical needs
    • Changes in lifestyle
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Use of alternative therapies
    • Adverse effects of drugs
    • Poor patient adherence
    • Stringent regulatory guidelines
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in public awareness
    • Increase in R&D
    • Use of off-label drugs
    • Patient assistance programs
  • Vendor landscape
    • Competitive scenario
    • F Hoffmann-La Roche
      • Table F Hoffmann-La Roche: Business segmentation 2014 by revenue
      • Table F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($billions)
      • Table F Hoffmann-La Roche: Geographical segmentation by revenue 2014
      • Table F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
      • Table F Hoffmann-La Roche: Key takeaways
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Business segmentation by revenue 2014
      • Table GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table GlaxoSmithKline: Geographical segmentation by revenue 2014
      • Table GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
    • Gilead Sciences
      • Table Gilead Sciences: Geographical segmentation by revenue 2014
      • Table Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
      • Table Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
      • Table Gilead Sciences: Key takeaways
    • Johnson & Johnson
      • Table Johnson & Johnson: Business segmentation by revenue 2014
      • Table Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Johnson & Johnson: Geographical segmentation by revenue 2014
      • Table Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
      • Table Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
      • Table Johnson & Johnson: Key takeaways
    • Merck
      • Table Merck: Business segmentation by revenue 2014
      • Table Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Merck: Geographical segmentation by revenue 2014
      • Table Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
      • Table Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
      • Table Merck: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report